Change of Adviser

PROTEOME SCIENCES plc

                                             PRESS RELEASE

For immediate release                                                            7th December 2005

                                           CHANGE OF ADVISER

Proteome Sciences plc ("Proteome" or the "Company")

Proteome announces today, 7 December 2005, that it has appointed Teather & Greenwood Limited
as its Nominated Adviser and Broker, in terms of the AIM Rules, with immediate effect.

                                                 ENDS

Enquiries:

Proteome Sciences plc                                 
www.proteomics.com                                    
Christopher Pearce, Chief Executive             Tel:  [phone]
                                              Email:  [e-mail]

Nominated Adviser and Broker to Proteome              
Teather & Greenwood Limited                           
Jeff Keating                                    Tel:  [phone]
Robert Naylor                                         

Public Relations for Proteome                         
IKON Associates                                       
Adrian Shaw                                     Tel:  [phone]
                                             Mobile:  [phone]
                                              Email:  [e-mail]

Notes to Editors:
Proteome  applies  high  sensitivity  proteomics to identify  and  characterise  differential  protein
expression  in  diseases  for  diagnostic, prognostic and therapeutic applications.  It  has  to  date
developed  sensitive  blood  assays  for  stroke, vCJD, BSE,  solid  organ  transplant  rejection  and
Alzheimer's   disease.   The   main   focus  of  its  research   currently   addresses   neurological,
neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions.

In  addition to its own proprietary biomarkers, Proteome Sciences has developed ProteoShop®  (Proteome
Sciences High Output Proteomics), a tool box that offers high sensitivity and high throughput gel  and
gel-free  proprietary technologies for the identification of potential biomarkers  and  drug  targets.
These include specialisation in membrane proteins and protein phosphorylation.

The  Company  has developed a range of specialist reagents to improve the performance and quantitation
of  protein  separation  and characterisation with mass spectrometry, bioinformatics,  statistics  and
pattern recognition. These include Sensitizer®, PST®, qPST® and TMT®.

Commercialisation  is  being  actively pursued across the portfolio of the  Company's  programmes  and
technologies with licensing deals signed in biomarkers for Stroke and TSEs and for ProteoSHOP®.

Proteome Sciences is headquartered in Cobham, Surrey in the UK and has laboratories at King's  College
Hospital,  London and in Frankfurt. It employs 40 full time scientists, in addition to  its  corporate
and business development staff. The Company is listed on AIM.

Proteome Sciences